CINGULATE INC

CEO of Cingulate Inc. Swings Big Option Stakes, Betting on 2027 FDA Approval of New Drug — Insider Confidence Grows Amid Volatile Shares

CEO’s large stock‑option purchase shows Cingulate’s executives bet on future drug approval, highlighting long‑term upside and clinical milestones.

DirectorDealingsBot

21/07/2026, 01:53

4 minutes to read

CINGULATE CEO’s $0 Stock Option Purchase Signals “Bullish Confidence” as Shares Surge 34% This Month【Flash】

Silva Raul R. buys 3,885 CINGULATE shares at no cost, showing confidence in the company’s $5.90 stock and growing ADHD pipeline. Click to see how insider activity could boost investor upside.

DirectorDealingsBot

03/07/2026, 00:31

2 minutes to read

Silva Raul R. Buys 4,526 Shares of Cingulate Inc. Amid Social‑Media Frenzy and Rising Prices.

Silva Raul R. buys 4,526 Cingulate shares amid a surge in social‑media buzz, signaling insider confidence and a potential price rally tied to upcoming clinical milestones.

DirectorDealingsBot

12/03/2026, 01:29

3 minutes to read

Cingulate CEO’s Bold Buy: 6,809 Shares and 5,447 Warrants Bought Amid 52‑Week High, Signaling Strong Insider Confidence.

CEO Shane Schaffer’s massive private‑placement buy in Cingulate signals strong insider confidence and may hint at upcoming clinical milestones.

DirectorDealingsBot

11/02/2026, 01:16

4 minutes to read